CellPoint is a biotechnology startup founded in 2018 with a focus on treating hematological malignancies by retargeting patient immune cells at the point-of-care. In 2022, CellPoint was acquired by Galapagos, a fully integrated biotechnology company, aiming to transform patient outcomes through life-changing science and innovation. Consequently, all company updates, news, and insights will be shared on Galapagos’ page. The acquisition information can be found in the press release from 22 June 2022 on Galapagos’ website. This move signifies a strategic alignment to accelerate access to next-generation cell therapies.
There is no investment information
No recent news or press coverage available for CellPoint.
We care about your data, and we'd love to use cookies make your experience better.